buspirone has been researched along with Disease Exacerbation in 2 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lundblad, M | 1 |
| Usiello, A | 1 |
| Carta, M | 1 |
| Håkansson, K | 1 |
| Fisone, G | 1 |
| Cenci, MA | 1 |
| Hassin-Baer, S | 1 |
| Korczyn, AD | 1 |
| Giladi, N | 1 |
2 other studies available for buspirone and Disease Exacerbation
| Article | Year |
|---|---|
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal | 2005 |
An open trial of amantadine and buspirone for cerebellar ataxia: a disappointment.
Topics: Adult; Aged; Amantadine; Buspirone; Cerebellar Ataxia; Clinical Trials as Topic; Disease Progression | 2000 |